Otsuka’s Centanafadine Edges Closer To US Nod Following Priority Review

First-In-Class, Non-Stimulant Option

 
• By Lisa Takagi
  
centanafadine priority review
Otsuka's novel ADHD drug granted US priority review (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip